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Abstract 
Background: The hedgehog signaling pathway is vital in early development, but then becomes 
dormant, except in some cancer tumours.  Hedgehog inhibitors are being developed for potential use 
in cancer.  Objectives/Methods: The objective of this evaluation is to review the initial clinical studies 
of the hedgehog inhibitor, GDC-0449, in subjects with cancer. Results: Phase I trials have shown that 
GDC-0449 has benefits in subjects with metastatic or locally advanced basal-cell carcinoma and in 
one subjects with medulloblastoma.  GDC-0449 was well tolerated.  Conclusions: Long term efficacy 
and safety studies of GDC-0449 in these conditions and other solid cancers are now underway.  
These clinical trials with GDC-0449, and trials with other hedgehog inhibitors, will reveal whether it is 
beneficial and safe to inhibit the hedgehog pathway, in a wide range of solid tumours or not. 
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1. Introduction 
In the modern era, drugs targeting molecules involved specifically in cancer, rather than drugs 
inhibiting the growth of all cells are preferred, as these drugs are less likely to cause adverse effects.  
The hedgehog pathway is vital in early development, but then becomes dormant, except in some 
cancer tumours.  This makes the hedgehog pathway a specific target in cancer.  Alterations in the 
hedgehog pathway have been linked to basal cell carcinomas, medulloblastoma, small cell lung, and 
gastrointestinal tract cancers [reviewed in 1].  Thus, drugs targeting the hedgehog pathway may be 
useful in the treatment of these cancers. 
In the hedgehog pathway, the hedgehog ligand binds to the patched receptor, and this binding allows 
the smoothened receptor to function as an inhibitory cell signal.  This inhibitory cell signaling includes 
the transcription factors Gli1 and Gli2, which induce the hedgehog target genes.  This pathway is an 
important regulator of cell growth and differentiation during development, but is then usually turned 
off.  The activity of the hedgehog system can be determined by measuring the levels of the 
transcription factors.   
Constitutive activity of the smothered receptor (without hedgehog ligand activation of the patched cell) 
in cancer leads to the proliferation of cells.  GDC-0449 binds to the constitutively active smoothened 
receptor in the hedgehog pathway in cancer, and this prevents proliferation of cells.  GDC-0449 is a 
potent inhibitor of the production of Gli1 (IC50=13 nM) [1]. 
This evaluation is of two clinical reports showing promise with GDC-0449 in human cancer.  Firstly, 
GLC-0449 has been studied in subjects with advanced basal-cell carcinoma [2], and this is discussed 
in the next section.  Secondly, there is a report of the effect of GDC-0449 in one subject with 
metastatic medulloblastoma [3], and this discussed in Section 3.  
2. GDC-0449 in advanced basal-cell carcinoma 
2.1 Introduction 
Basal-cell carcinoma is the most common type of skin cancer.  There are about 800,000 new cases 
each year in the US, and up to 30% of Caucasians develop basal cell carcinomas in their life time.  
Basal-cell carcinoma rarely cause death, but can be responsible for disfiguration and invading, then 
destruction, of local tissues. 
Normally, the hedgehog pathway is inactive in adult tissues.  However, in basal-cell carcinoma, there 
are mutations of the components of the hedgehog signaling pathway, such that it is constitutively 
active.  Activity of the hedgehog pathway in basal-cell carcinomas leads to unrestrained proliferation 
of basal cells of the skin.  Thus, inhibition of the hedgehog pathway with GDC-0449 may be beneficial 
in basal-cell carcinoma. 
2.2 Methods and results 
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The methods and results of the Phase I trial showing that GDC-0449 may have anti-tumour activity in 
basal-cell carcinoma [2] are combined in this section.  The trial was open-label, and performed in 68 
subjects with solid tumours refractory to standard treatment (surgery, radiotherapy or systemic 
therapy), and 33 of these subjects had metastatic or locally advanced basal-cell carcinoma.  
In stage 1 of the trial, after a single oral dose of GDC-0449 on day 1, there was no further treatment 
until day 8 when the daily administration of the same dose was commenced.  The doses were 150 
mg/day for 7 subjects, 270 mg/day for 9, and 540 mg/day for 4 subjects.  Of these subjects, only one 
in each group had metastatic or locally advanced basal-cell carcinoma.  Interestingly, two of the three 
showed clinical benefit during stage 1.  With these doses, there were no dose-limiting toxic effects or 
intolerability.  
In stage 2 of the trial, 30 more subjects with metastatic or locally advanced basal-cell carcinoma were 
added to the 3 from stage 1.  Of these new subjects, 20 were treated with GDC-0449 150 mg or 270 
mg/day, and the other 10 received a new formulation of GDC-0449 150 mg/day.  This study ran for 
9.8 months. 
For the 15 subjects with metastatic tumours that could be measured radiologically, tumour 
measurement was performed at baseline, and then every 8 weeks, with the use of the Response 
Evaluation Criteria in Solid Tumours.  Using this scale, 7 of the 15 subjects had partial responses (a 
reduction of more than 50% in the tumour diameter).   
For subjects where metastatic tumours could not be measured radiologically, the tumours were 
assessed physically.  Two of the 3 subjects, with metastatic tumours that could not be measured 
radiologically, had partial responses on physical examination.   
For the subjects with locally advanced tumours, 2 were assessed radiologically and 13 by physical 
examination.  Two subjects had a complete clinical response, 7 had a partial clinical response, 4 had 
stable disease, and 2 had progressive disease. 
Adverse events were assessed using the National Cancer Institutes’ Common Terminology Criteria 
for Adverse Events.  Grade 4 asymptomatic hyponatremia occurred in one subject.  The most 
common grade 3 adverse events were fatigue (4 subjects), and hyponatremia, weight loss and 
dyspnoea (2 subjects each). 
Blood samples were taken to determine plasma levels of GDC-0449.  There was no obvious dose-
related effect.  The median time to steady state was 14 days, regardless of dose. 
The effectiveness of GDC-0449 in inhibiting the hedgehog pathway was assessed by measuring GLI1 
expression on RNA extracted from non-involved skin at baseline and after 21 days.  A decrease in 
GLI1 expression by more than a factor of 2 from baseline was observed in biopsies of skin from 10 of 
13 subjects who participate in this part of the study. 
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In tumour-biopsy specimens, it was shown that GLI1 mRNA expression levels were similarly high in 
25 of 26 subjects tested, as previously reported for this condition. 
3. GDC-0449 in medulloblastoma 
3.1 Introduction 
Medulloblastoma is a highly malignant primary brain tumour, which originates in the cerebellum.  
Medulloblastoma occurs primarily in children, and is the most common malignant brain tumour in 
children.  Medulloblastoma is treated by resection, followed by radiation and chemotherapy.  Although 
treatment may permit a 5 year survival in more than 80% of cases, this is often accompanied by 
severe adverse events such as postoperative mutism, neurocognitive deficits, dysfunction of 
endocrine organs, sterility, and the risk of secondary high-grade glioma or meningioma.  
Medulloblastoma seems to arise from stem cells or early progenitor cells in the cerebellum.  Activation 
of the hedgehog pathway in these cells leads to the expansion, migration, and differentiation of 
immature precursor cells from the external granule-cell layer to form the internal granule-cell layer.  
As, in basal-cell carcinoma, there are mutations of the components of the hedgehog signaling 
pathway in medulloblastoma, so that it is constitutively active [reviewed in 3]. 
3.2 Case report 
The case report of GDC-0449 in medulloblastoma [3] is summarised in this section.  The subject had 
been diagnosed with medulloblastoma at age 22, and had received extensive treatment for the 
condition by age 26.  This included resection, irradiation, and chemotherapy (carboplatin, etoposide, 
cyclophosphamide, and vincristine).  Despite this treatment, recurrent and metastatic disease was 
confirmed at age 24.  This time the subject was treated with induction etoposide, temozolomide, and 
cyclophosphamide, and this gave a partial response. However, 18 months later, the subject had 
widespread systemic disease development, but not in the central nervous system.  The subject was 
treated by surgery, radiosurgery, and systemic drug treatment.  The systemic drug treatment of 
temozolomide and bevacizumab was stopped due to refractory pancytopenia. 
By April, 2008, the subject was 26 and had considerable bone pain despite treatment with oxycodone.  
He also has enlarged lymph nodes above his left collar bone, thickened masses around the breast 
bone, and pancytopenia.  The subject was receiving transfusions of platelets twice a week, and of 
packed red blood cells once a week. 
The subject initially received a single dose of GDC-0449 540 mg, and then one week later was put on 
GDC-0449 daily.  After about 3 weeks of treatment, the lymph nodes were no longer enlarged, one of 
masses could no longer be felt, and the other mass had reduced in size, and there was no pain.  The 
pancytopenia did persist, but was able to be treated with one transfusion per week. 
Unfortunately, 3 months after starting the treatment with GDC-0449, it stopped working, and there 
was disease progression.  The subject died 2 months later.  Molecular biology studies of the subjects 
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metastatic tumour prior to treatment with GDC-0449 were suggestive of an overactive hedgehog 
signaling pathway. 
3.3 Discussion 
A subsequent study investigated the mechanism underlying the resistance that developed to GDC-
0449 [yauch09].  The study used the tumour from the subject with medulloblastoma when there was 
progression of disease, despite continuing treatment with GDC-0449 [4].  The study showed an amino 
acid substitution at a conserved aspartic acid residue of the smothered receptor, and this substitution 
prevented binding of the GDC-0449 to the smoothened receptor [4]. This acquired mutation prevented 
GDC-0449 from inhibiting the hedgehog signaling pathway, and lead to the disease progression [4].   
4. Expert opinion 
 
4.1 What happened in the other subjects with solid tumours treated? 
In stage 1 of the trial, there were 20 subjects with solid tumours, of which only three has basal-cell 
carcinoma, and two of these showed improvement [2].  Presumably, the other 17 subjects with solid 
tumours did not have improvement with GDC-0449.  It would be on interest to know which solid 
tumours did not show improvement with GDC-0449.  This may prevent the testing of GDC-0449 in 
other subjects with these tumours. 
4.2 Ongoing clinical trials with GCD-0449 in basal cell carcinoma and medulloblastoma 
There are clinical trials in progress with GDC-0449 in basal cell carcinoma and medulloblastoma.  For 
instance, there is a Phase II long term study evaluating the efficacy and safety of GDC-0449 in 
subjects with advanced basal cell carcinoma [5].  With regard to medulloblastoma, GDC-0449 is being 
tested in a Phase II trial in adult subjects with recurrent or refractory medulloblastoma [6], and in a 
Phase I trial of young patients with medulloblastoma that is recurrent and did not respond to previous 
treatment [7]. 
4.3 Which other cancers will GDC-0449 be effective in? 
At present, we do not know which cancers GDC-0449 will be effective in, but we do know that the 
hedgehog pathway is activated in tumours of about 25% of all cancer deaths [8].  In addition to the 
basal cell carcinoma and medulloblastoma, activation of the hedgehog pathway has been observed in 
human glioblastoma, pancreatic cancer, prostate cancer [8], small cell lung and gastrointestinal tract 
cancers [1]. A Phase I trial of the combination of GDC-0449 and erlotinib in subjects with metastatic 
pancreatic cancer or solid tumours that cannot be removed by surgery is underway [9].  A clinical trial 
of GDC-0449 in treating patients with recurrent glioblastoma multiforme that can be removed by 
surgery is planned [10].  GDC-0449 is also being trialled in advanced stomach cancer or 
gastroesophageal junction cancer, solid tumours per se, extensive-stage small cell lung cancer, 
metastatic colorectal cancer, and ovarian cancer [10].   
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4.4 Other hedgehog inhibitors 
A major problem with GDC-0449 in the treatment of medulloblastoma was that resistance developed. 
There are many other hedgehog inhibitors in development [8], and hopefully some of these will either 
develop less resistance or be effective in GDC-0449 resistance.  Thus, although, GDC-0449 
(Genetech, a member of the Roche Group), is the most developed hedgehog inhibitor to date, other 
agents are entering clinical trial.  These include LDE225 (Novartis) [11] and IPI-926 (Infinity 
Pharmaceuticals) [12], which are in Phase I for advanced solid tumours, and PF-04449913, which is 
in Phase I for select hematologic malignancies [13].  
4.5 Conclusions 
These initial reports of benefits with the hedgehog inhibitor GDC-0449 either for subjects with 
advanced basal-cell carcinoma or a subject with medulloblastoma are very interesting.  Long term 
efficacy and safety studies in these conditions are now underway.  GDC-0449, and other hedgehog 
inhibitors, are entering clinical trials for a range of solid tumours.  The next few years are going to be 
an exciting time for hedgehog inhibitors, as clinical trials reveal whether they are beneficial and safe in 
a wide range of solid tumours or not. 
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